Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2019

View Archived Issues

Arcturus receives additional support from CF Foundation to develop mRNA therapies to treat CF

AC Immune initiates phase Ib/IIa study of ACI-35.030 vaccine for the treatment of AD

VHIO and BST co-launch clinical trial of ViroTCell

UBL4A acts as an authophagy inhibitor and tumor suppressor in pancreatic ductal adenocarcinoma

Vacuolar protein sorting 35 is a regulator of tau phosphorylation and neuropathology

Novel VEGFR-2 inhibitors show significant antiproliferative activity in preclinical models

Oncoceutics reports phase I data for ONC-201

Better blood diagnostics with a different Holmes

A spoonful of sugar helps immunity calm down

MolMed describes chimeric antigen receptors targeting CD44

ALDH1 antigen-pulsed dendritic cells created at the University of Michigan

AC Immune patents agents targeting misfolded human TAR DNA-binding protein 43

Sosei Heptares and Takeda enter into new strategic partnership

California Institute of Technology, University of Tennessee present DPAGT1 inhibitors

Idorsia Pharmaceuticals identifies C5aR antagonists

Cancer research leads to pregnancy insights

FDA approves Turalio as first therapy for rare and debilitating joint tumor

Phase III IMvigor130 study of Tecentriq meets coprimary endpoint

Trifunctional natural killer cell engagers targeting tumor antigens control tumor growth in vivo

Pivotal phase III RESET study of rivipansel does not meet primary nor key secondary endpoints

Positive phase II data presented for dry powder inhaler formulation of ensifentrine

Analysis of phase III study of masitinib in melanoma carrying a mutation in JM domain of c-Kit

Telix Pharmaceuticals and DKFZ enter into collaboration agreement for image-guided prostate surgery

Poxel initiates PK/PD trial as part of its phase IIa clinical program for PXL-770

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...